Journal of Surgical Oncology最新文献

Introduction: Hepatic artery infusion chemotherapy (HAIC) has been used in efforts to improve outcomes in patients with locally advanced cholangiocarcinoma. Reported experiences are generally small institutional series. The efficacy of HAIC in locally advanced cholangiocarcinoma is not well defined.

Methods: We performed a comprehensive search using the electronic databases PubMed, Embase, Cochrane, ClinicalTrials. Gov, and WHO Clinical Trials from inception to August 2024.

Results: A total of 202 publications were screened, with 15 studies representing 588 patients meeting the inclusion criteria. Most patients demonstrated either a partial response or stable disease after therapy (CR: 2.5%, PR: 38.1%, SD: 43.4%, PD: 12.7%, NA: 3.3%). Meta-analysis found a pooled median overall survival of 18.3 months (95% CI: 14.1-22.4 months) and progression-free survival of 10.0 months (95% CI: 7.7-12.3 months).

Conclusion: HAIC demonstrates an improvement over reported survival for systemic chemotherapy alone when used as either an adjunct or in place of systemic therapy for first-line treatment in patients with cholangiocarcinoma.

Background and objectives: Osteoid Osteoma (OO) is a painful, benign bone tumor that can be treated surgically with en bloc resection, curettage, and radiofrequency ablation (RFA). This study aims to measure recurrence rates after initial treatment by treatment type and to examine clinical factors associated with recurrence.

Methods: A retrospective review of patients with an OO diagnosis was performed using a pathology database from a tertiary pediatric hospital between November 1, 2004 and July 1, 2024. Statistical analysis examined the relationships among surgical technique, recurrence, and clinical variables.

Results: 24 patients met inclusion criteria with a median follow-up of 1.41 years (interquartile range, IQR 2.0) and a median age at treatment of 9.92 years (IQR 5.8-13.5). Twelve patients (50.0%) experienced symptomatic tumor recurrence, with a median time to recurrence of 0.92 years (IQR 0.1-3.0). Of those with tumor recurrence, five patients were initially treated with excision and curettage, while the remaining nine underwent RFA. There was no significant correlation between recurrence and surgical intervention (p = 0.667), age at initial surgery (p = 0.468), or patient sex (p = 0.667).

Conclusions: Surgical management of pediatric OO is linked to high recurrence rates, and recurrence is not related to surgical intervention, age, or patient sex.

Background: We assessed overall survival (OS) and cancer-specific-survival (CSS) of radical resection compared to local excision for stage 1 rectal cancer in very old patients (≥ 80 years).

Methods: This retrospective cohort study included patients aged ≥ 80 years who underwent surgery for stage 1 rectal cancer from the SEER database from 2000-2020. Patients were divided into radical resection and local excision groups, and were exact matched for T stage, tumor grade, and tumor size. The main outcome measures were OS and CSS.

Results: 6379 patients ≥ 80 years underwent local or radical resection of stage 1 rectal cancer; 51.9% were female and 47% had T1 tumors. After matching, 1125 patients were included in each group. The median OS was longer in patients who underwent radical resection (60 months vs. 51 months, p = 0.009), yet there were no significant differences in CSS between the two groups. When stratified by the T stage, there was no benefit for radical resection in T1 tumors (p = 0.33). In multivariate analysis, radical resection and local excision had similar hazard of mortality (HR 1.03, 95%CI 0.76-1.38).

Conclusion: Radical resection and local excision had similar CSS in very old patients with stage 1 rectal cancer. A personalized approach considering patient status and treatment goals should be used for each patient.

Background and objectives: Tumor involvement of the posterior mandible often requires resection of the mandibular condyle and associated soft tissue. This study explores clinical and patient-reported outcomes (PROs) associated with condyle preservation versus resection during reconstruction.

Methods: This retrospective cohort study examined patients who underwent bony free flap reconstruction of posterolateral mandible defects from 2017 to 2021. Major clinical outcomes included length of stay (LOS), duration of follow-up, cancer recurrence, and all-cause mortality. PROs were assessed using the validated FACE-Q Head and Neck Cancer module survey for overall, short-term (0-1 year postoperatively), and long-term (> 1 year postoperatively) outcomes. The cohorts included (1) condyle preservation, (2) condyle resection with condyle autotransplantation, and (3) condyle resection without autotransplantation.

Results: 94 patients were included in the study. Major clinical outcomes did not significantly differ between cohorts (all p > 0.439). Compared to the condyle-resected cohort, condyle-preserved patients overall reported superior Overall Facial Appearance (p = 0.035), Eating Function (p = 0.034), Appearance/Face Distress (p = 0.020), Eating Distress (p = 0.017), and Cancer Worry (p = 0.002). Long-term assessments revealed more marked advantages for in-situ condyle preservation compared to condyle resection in Overall Facial Appearance (p = 0.022), Eating Function (p = 0.004), Smiling Function (p = 0.035), Swallowing Function (p = 0.003), Eating Distress (p = 0.006), and Cancer Worry (p = 0.011). Among condyle-resected patients, condyle autograft did not significantly improve FACE-Q scores (all p > 0.177).

Conclusions: In-situ condyle preservation yielded superior PROs compared to condyle resection ± condyle autograft, particularly over 1 year postoperatively. Major clinical outcomes did not significantly differ.

Locally advanced breast carcinoma (LABC) is a frequent condition in Brazil and in developing countries. Neoadjuvant systemic therapy (NST) has allowed for surgical de-escalation of the breast and/or axilla, leading to increasing the rates of breast-conserving-surgery, skin/nipple preservative mastectomies and axillary preservation. There are no established quality indicators for LABC or NST. This article aimed to review the topic, highlighting Brazilian studies, identifying thirty potential quality indicators for surgical treatment.

Breast cancer remains a leading cause of cancer-related mortality among women globally. Vietnamese women experience unique challenges, including sociocultural, linguistic, and systemic barriers, contributing to disparities in screening utilization, late-stage diagnoses, and treatment outcomes. Despite advances in early detection and care, inequities persist. A systematic review was conducted following PRISMA guidelines, with the protocol registered on PROSPERO. PubMed, Embase, and Scopus were searched for original studies published from 2000 to 2024 examining breast cancer screening, outcomes, molecular/genetic features, and disparities in Vietnamese populations. Narrative synthesis was employed due to heterogeneity in study metrics and methodologies. Forty-one studies encompassing 39,324 Vietnamese participants (mean age 48.15 ± 7.48 years) were included. Social networks and acculturation positively influenced screening uptake, while systemic barriers such as language, cultural stigma, and lack of insurance deterred participation. Across included studies, mammography screening rates among Vietnamese women ranged widely from 26% to 83%, consistently lower than the U.S. national average of 81%, and lower than rates reported in many Asian American subgroups. Late-stage diagnoses were prevalent, occurring in 32.9% of Vietnamese women, with foreign-born Vietnamese women exhibiting higher mortality than U.S.-born counterparts. Molecular studies revealed distinct tumor subtypes, including higher HER2-positive and triple-negative breast cancer rates. Interventions, including culturally tailored education and patient navigator programs, demonstrated success in addressing screening and care disparities. Vietnamese women face significant breast cancer disparities driven by sociocultural, systemic, and biological factors. Effective solutions require integrating culturally tailored solutions to promote equitable outcomes and reduce disparities in breast cancer care.

Introduction: Elective neck dissection (END) for oral tongue squamous cell carcinoma (OTSCC) typically involves level 4 due to potential metastases that may bypass levels 1-2. Our study challenges this notion and investigates the necessity of level 4 inclusion in END for OTSCC.

Methods: A retrospective cohort study performed in a tertiary-care university affiliated medical center and included all OTSCC patients treated with END from 2000 to 2020, with a minimum 2-year follow-up. The study compared patients with END levels 1-3 to those with levels 1-4 regarding regional recurrence, disease-specific and disease-free survival rates.

Results: 120 patients with OTSCC and clinically negative neck were included. END included levels 1-4 in 33 patients (27.5%) and levels 1-3 in the remaining 87 patients (72.5%). Out of all 33 patients who underwent END of levels 1-4, only 1 patient had level 4 metastasis (3%). There was no significant difference in the regional recurrence rate (21.8% vs. 18.2%, p = 0.66) and level 4 recurrence rate (3.5% vs. 3%, p = 0.91) between the groups. No difference regarding 5-years overall, disease-specific, and disease-free survival was demonstrated between the 1-3 END and 1-4 END groups (69.3% vs. 61.1%, Log-rank p = 0.7, 82% vs. 66.2%, Log-rank p = 0.15% and 66.4% vs. 60.7%, Log-rank p = 0.54, respectively).

Conclusion: Inclusion of level 4 in the elective neck dissection for OTSCC does not seem to improve regional control, disease-free and overall survival. Hence, elective neck dissection of levels 1-3 seems appropriate for most cases of OTSCC, as for other oral cavity subsites.

Hanson, N., Farmer, W., Andres, M., Franko, J. and Le, V. (2025), Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature. Journal of Surgical Oncology, 131: 1074-1080. https://doi.org/10.1002/jso.27925

In Figure 1, the Prisma Flow Diagram, there was an error in the tabulated numbers. The final number of review articles was 29, but the number of removed articles stated 165. This was an error in calculation, and it was actually 163 from the original 192 to get 29.

The corrected figure is shown below.

We apologize for this error.

Filho GVdM, Costa GJ, Martins MR, Torres LC. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. J Surg Oncol. 2024; 130: 913-918. https://doi.org/10.1002/jso.27758.

In paragraph 2.1 of the Methods section, add a third paragraph to the text “The criteria for exclusion were pregnant or lactating patients, patients with psychiatric disorders, patients with a clinical history of HIV I/II or HTLV I/II infection, patients with a clinical history of autoimmune or infectious diseases, patients with a previous diagnosis and treatment for another type of malignant tumor and patients who had undergone prior chemotherapy, immunotherapy, or radiotherapy.

In paragraph 2.3 of the Methods section, remove the incorrect paragraph “A Kaplan–Meier curve with log-rank test was performed for survival time between sGal-9 ≤ 1,694 and > 1,694 groups and smoking status (smokers vs non-smokers)” and replace it with the text “The median survival time was calculated using a specific Gal9 cutoff value. The median survival using the Gal9 cutoff less than or equal to 1694 pg/mL was 15.9 months and undefined for the above cutoff point 1694 pg/mL.”

We apologize for these errors.